For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication ...

The findings, published in The Lancet, establish pembrolizumab as a new option for patients with this disease. "Soft tissue sarcoma is a rare and complex disease with over 50 different subtypes ...

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Bicycle Therapeutics (BCYC) announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously ...

The immune checkpoint inhibitor pembrolizumab may reduce this risk. New research findings are summarized in a short video.

(Pembrolizumab + vibostolimab) is under clinical development by Merck and currently in Phase II for Metastatic Colorectal Cancer.

Updated overall survival data from KEYNOTE-564 showed adjuvant pembrolizumab benefits in clear cell renal cell carcinoma, but some patients remain unresponsive.

FYB-206 is under development for the treatment of malignant melanoma (black skin cancer) and non-small cell lung cancer. The drug candidate is a pembrolizumab biosimilar. It acts by targeting ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

(RTTNews) - Bicycle Therapeutics plc (BCYC), Monday announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) ...